987 related articles for article (PubMed ID: 19589874)
41. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Aug; 94(8):1694-704. PubMed ID: 15986467
[TBL] [Abstract][Full Text] [Related]
42. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats.
Yokooji T; Murakami T; Yumoto R; Nagai J; Takano M
J Pharm Pharmacol; 2007 Sep; 59(9):1263-70. PubMed ID: 17883898
[TBL] [Abstract][Full Text] [Related]
43. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.
Xia CQ; Liu N; Yang D; Miwa G; Gan LS
Drug Metab Dispos; 2005 May; 33(5):637-43. PubMed ID: 15716365
[TBL] [Abstract][Full Text] [Related]
44. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1.
Zamek-Gliszczynski MJ; Hoffmaster KA; Tian X; Zhao R; Polli JW; Humphreys JE; Webster LO; Bridges AS; Kalvass JC; Brouwer KL
Drug Metab Dispos; 2005 Aug; 33(8):1158-65. PubMed ID: 15860656
[TBL] [Abstract][Full Text] [Related]
45. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
46. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.
Makhey VD; Guo A; Norris DA; Hu P; Yan J; Sinko PJ
Pharm Res; 1998 Aug; 15(8):1160-7. PubMed ID: 9706044
[TBL] [Abstract][Full Text] [Related]
47. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs.
Sha X; Fang X
Int J Pharm; 2004 Mar; 272(1-2):161-71. PubMed ID: 15019079
[TBL] [Abstract][Full Text] [Related]
48. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
49. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine.
Okudaira N; Komiya I; Sugiyama Y
J Pharmacol Exp Ther; 2000 Nov; 295(2):717-23. PubMed ID: 11046110
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
[TBL] [Abstract][Full Text] [Related]
51. Flavonoid permeability across an in situ model of the blood-brain barrier.
Youdim KA; Qaiser MZ; Begley DJ; Rice-Evans CA; Abbott NJ
Free Radic Biol Med; 2004 Mar; 36(5):592-604. PubMed ID: 14980703
[TBL] [Abstract][Full Text] [Related]
52. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
53. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
54. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
[TBL] [Abstract][Full Text] [Related]
55. Site-specific bidirectional efflux of 2,4-dinitrophenyl-S-glutathione, a substrate of multidrug resistance-associated proteins, in rat intestine and Caco-2 cells.
Yokooji T; Murakami T; Yumoto R; Nagai J; Takano M
J Pharm Pharmacol; 2007 Apr; 59(4):513-20. PubMed ID: 17430634
[TBL] [Abstract][Full Text] [Related]
56. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
57. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.
Agarwal S; Pal D; Mitra AK
Int J Pharm; 2007 Jul; 339(1-2):139-47. PubMed ID: 17451894
[TBL] [Abstract][Full Text] [Related]
58. Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug.
Jin HE; Song B; Kim SB; Shim WS; Kim DD; Chong S; Chung SJ; Shim CK
Xenobiotica; 2013 Apr; 43(4):355-67. PubMed ID: 23020787
[TBL] [Abstract][Full Text] [Related]
59. Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
Johnson BM; Charman WN; Porter CJ
Drug Metab Dispos; 2003 Sep; 31(9):1151-60. PubMed ID: 12920171
[TBL] [Abstract][Full Text] [Related]
60. Ochratoxin A secretion by ATP-dependent membrane transporters in Caco-2 cells.
Schrickx J; Lektarau Y; Fink-Gremmels J
Arch Toxicol; 2006 May; 80(5):243-9. PubMed ID: 16244858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
